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Abstract
Evolutionary perspectives on menopause have focused on explaining why early reproductive cessation in
females has emerged and why it is rare throughout the animal kingdom, but less attention has been given
to exploring patterns of diversity in age at natural menopause. In this paper, we aim to generate new
hypotheses for understanding human patterns of diversity in this trait, defined as age at final menstrual
period. To do so, we develop a multilevel, interdisciplinary framework, combining proximate, physio-
logical understandings of ovarian ageing with ultimate, evolutionary perspectives on ageing. We begin
by reviewing known patterns of diversity in age at natural menopause in humans, and highlight issues
in how menopause is currently defined and measured. Second, we consider together ultimate explanations
of menopause timing and proximate understandings of ovarian ageing. We find that ovarian ageing is
highly constrained by ageing of the follicle – the somatic structure containing the oocyte – suggesting
that menopause timing might be best understood as a by-product of ageing rather than a facultative adap-
tation. Third, we investigate whether the determinants of somatic senescence also underpin menopause
timing. We show that diversity in age at menopause can be, at least partly, explained by the genetic, eco-
logical and life-history determinants of somatic ageing. The public health implications of rethinking
menopause as the by-product rather than the catalyst of biological ageing are discussed.
Keywords: Reproductive cessation; life-history; biocultural; somatic ageing; age at menopause; ovarian ageing
Media summary: Variation in age at natural menopause might be best understood as a by-product of
differing rates of somatic ageing.
1. Introduction
Menopause, as per the World Health Organisation definition (NCC-WCH, 2015), refers to the
permanent cessation of menstruation in human females. While natural menopause is a ubiquitous
phenomenon of the human female ageing experience, there is considerable variation in the timing
of menopause (or age at menopause), and how menopause is experienced both within, and between
populations (Jasienska, Bribiescas, Furberg, Helle, & Núñez-de, 2017; Laisk et al., 2018; Monteleone,
Mascagni, Giannini, Genazzani, & Simoncini, 2018; Sievert, 2006). To date, most research into meno-
pause focuses either on the evolutionary emergence of menopause as a Darwinian puzzle or on the
proximate determinants of ovarian ageing. Surprisingly, there have been only limited attempts at
understanding patterns of diversity in age at natural menopause. This paper aims to address this deficit
by developing an interdisciplinary and multilevel framework combining proximate, biomedical
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understandings of menopause with an ultimate, evolutionary ecology perspective. Considering how
diversity in age at menopause is produced at one level (i.e. physiological) can help generate new
hypotheses at the evolutionary level (i.e. evolutionary and ecological drivers), and vice versa. Here
we build on ovarian ageing research to uncover the evolutionary ecological determinants of variation
in menopause timing. In turn, we hope to stimulate a new research programme investigating whether
menopause timing is best predicted by ecological models of somatic ageing.
What is menopause?
In the biomedical and population health sciences, natural menopause is defined as an event reached
when a woman has not had a menstrual cycle for the past 12 months (Hillard et al., 2017). Following
this final menstrual period (FMP), a woman is considered to have experienced menopause. Natural
menopause, which indicates the cessation of reproductive function, most often occurs in the fourth
or fifth decade of a woman’s life. While menopause itself is the complete cessation of periods, it is
best understood as a process rather than an event (Sievert, 2006). Indeed, individuals will be peri-
menopausal for some years before and after their FMP. Menopause is preceded by peri-menopause,
a time period characterised by the irregularity of menstrual cycle length and frequency
(Paramsothy et al., 2017) and the potential to experience vasomotor symptoms (e.g. hot flushes/
night sweats; Hillard et al., 2017), urogenital discomfort, anxiety, depression and joint aches
(Hillard et al., 2017). Note that not all women experience natural menopause, as some women may
experience menopause owing to a pathology of the reproductive system before the expected age of ces-
sation of reproductive function, or accelerated surgical menopause owing to procedures such as bilat-
eral oophorectomy, hysterectomy, chemotherapy or GnRH analogues (Hillard et al., 2017).
From an evolutionary standpoint, menopause is often equated with another feature of the female
reproductive lifespan – age at last birth. Most evolutionary approaches investigating the origins of
menopause focus on the cessation of fertility rather than the cessation of reproductive function
per se, especially in non-menstruating species. While reproductive capacity may coincide with age
of last birth in other species displaying early reproductive cessation, e.g. the killer whale (Orcinus
orca; Cant & Croft, 2019; Croft et al., 2017), menopause and age at last birth do not always coincide
in humans: an individual becomes post-fertile following their last birth, but they are not necessarily
post-reproductive if they are still cycling (Figure 1; Levitis, Burger, & Lackey, 2013). Indeed, the
two phases are reached on average 10 years apart in contemporary populations (Towner, Nenko, &
Walton, 2016), and there is only limited correlation between age at last birth and age at menopause
(reviewed in Towner et al., 2016). Thus, one cannot assume that the cessation of fertility is dependent
solely on physiological reproductive decline. Rather, age at last birth is influenced by sociocultural and
biological factors other than reproductive senescence (Bongaarts, 1978), including exposure factors
(partner availability), deliberate fertility control factors (family planning, induced abortion) and nat-
ural fertility factors (lactational infecundability, frequency of intercourse, pathological sterility, spon-
taneous intrauterine mortality; Bongaarts, 1978).
The extent to which age at menopause and age at last birth are determined by the same factors is
unclear owing to a paucity of studies considering the two traits together and thus whether the same
predictive framework should be applied to both age at last birth and age at FMP remains an open
question. To address this gap, in the remainder of this paper, we focus on age at natural menopause,
i.e. the age at FMP, rather than age at last birth.
Human variation in age at natural menopause
Self-reported age at menopause is variable, with mean age throughout the twentieth century being
anywhere between 44.6 and 54.5 years of age across different geographical regions (Laisk et al.,
2018), and between 46 and 51.7 years of age in studies conducted between 1990 and 2010
(Figure 2). Temporal changes in age at FMP occur across different birth cohorts, with a cohort
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study in Sweden identifying a 1 month increase of menopausal age with each year of birth (Rodstrom
et al., 2003). While there seems to be significant variation worldwide in age at menopause, the data
underpinning this picture are somewhat problematic owing to methodological considerations, includ-
ing an overrepresentation of clinical based studies in the global North, debatable inclusion/exclusion
Figure 1. Measuring post-reproductive lifespan: the differences between post-fertile lifespan (PFLS) and post-reproductive lifespan
(PRLS). ALB, Age at last birth; AM, age at menopause; AD, age at death. Post-fertile lifespan is defined as the length of time between
age at last birth, which typically occurs between 39 and 41 years (reviewed in Towner, Nenko, & Walton, 2016) and age at death. In
contrast, post-reproductive lifespan is defined as the length of time between age at menopause and age at death. Reproductive
senescence corresponds to fertility decline over age, which culminates in the age at menopause (AM). Note that this is not the same
as age at last birth. Arguments regarding the evolution of menopause – focusing on age at last birth – may not hold for explaining
diversity in the timing of menopause.
Figure 2. Variation in final menstrual period (FMP). This map was replicated from Laisk et al. (2018), with additional segregation of
data based on the decade in which it was collected. Variation in self-reported mean age at FMP is measured between 1990 and
2010 across countries. Broadly, mean age of menopause is higher in the Global North than in the Global South, but owing to the
lack of measurement of age at menopause across populations, there is a sizeable uncertainty associated with this pattern.
Additionally, the measurement of age at menopause in the studies included here may also be subject to limitations (discussed
in Box 1). See Supplementary Information for references, sample sizes and years during which the data were collected.
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criteria, data binning bias and cross-cultural bias (Box 1). Thus, much of the literature reviewed in this
paper is only approximating global variation in menopause timing.
Epidemiological studies, for the most part conducted in high-income countries and based on clin-
ical rather than population-based samples, shed some light on the macro-level determinants of meno-
pause timing. First, genetic contribution to age at menopause appears modest: GWAS-identified loci
only explain 2.5–4.1% of population variation in menopause timing (Stolk et al., 2012), suggesting that
genetic diversity holds little explanatory power for understanding diversity in age at menopause (but
see Section 3 on the genetics of longevity). Other studies identified mixed associations between meno-
pausal age and reproductive life history, socioeconomic status and lifestyle factors. For instance, early
Box 1: Methodological considerations when measuring age at menopause
Advancing knowledge of current patterns of diversity in menopause timing requires population-based studies to be
conducted outside the Global North. In addition, there are several limitations to both measuring menopause (e.g. age
at FMP) within populations and interpreting the results. Those issues, listed below, should be addressed in future
studies:
(i) The measurement of FMP may only be confirmed retrospectively. This increases the difficulty of recruiting women
who are newly post-menopausal for cross-sectional studies. Additionally, many current cohort studies use the
midpoint between two cohort waves where menstruation is present and then absent as age at FMP. Such data
are then often analyzed using discrete categories or ‘binning’ (eg. <45, 46–50, 51–55, 56+), which may obscure
any smaller trends in age at menopause.
(ii) A woman’s true age at menopause may be masked pharmaceutically (FSRH, 2017; Hillard et al., 2017).
(a) If a woman is taking combined oral contraceptives or hormone replacement therapy, bleeds are not
menstrual cycles but rather withdrawal bleeds under the control of medication (FSRH, 2017). Prescription
guidelines advise a change away from combined oral contraceptives to a progesterone-based contraceptive
over the age of 50 (or 35 for smokers or people with other risk factors; Hillard et al., 2017), given the high
risk of thromboembolism (FSRH, 2017). After this, bleeding may stop, and the individual may be considered
post-menopausal. However, any bleeding experienced while on oral contraception is a withdrawal bleed,
and a woman’s reproductive capacity may have ceased prior to stopping oral contraceptive usage.
(b) Similarly, the use of combined hormone replacement therapy (HRT) during the peri-menopausal stage can
also produce withdrawal bleeds (Hillard et al., 2017). These examples highlight the importance of defining
menopause as the cessation of menstrual cycles, rather than all forms of bleeding, as bleeding can also
originate from the use of hormonal contraceptives and HRT.
(c) If a woman is using progesterone-only contraceptive methods, age at menopause may also be masked by
amenorrhoea produced by contraceptive usage. This is potentially a frequent issue: the chance of
amenorrheoa by 12 months using the Mirena/levonorgestrel releasing intra-uterine system (the hormonal
coil) is 20–80%, and this form of contraception has the highest continuation rates in women aged 39–48
(Currie, 2019).
These examples highlight the importance of defining menopause as the cessation of menstrual cycles, rather than all
forms of bleeding, as bleeding can also originate from the use of hormonal contraceptives and HRT.
(iii) A woman’s true age at menopause can be difficult to identify. It is possible that during peri-menopause a
woman may not have a period in 12 months, then experience bleeding. The irregularity of menstrual cycles
may result in periods longer than 12 months where a woman appears to be anovulatory, especially towards
the later peri-menopause when menstrual cycles tend to be longer (Harlow & Paramsothy, 2011). While this
bleeding may be considered a period, it may not be a menstrual cycle but the result of reproductive
malignancies which can occur in the post-menopausal body (Hillard et al., 2017). Furthermore, menstrual
cyclicity amongst women is often more variable than a consistent 28 day cycle throughout reproductive life
(Gorrindo et al., 2007; Kato et al., 1999). This is especially pertinent amongst contemporary natural fertility
populations where menstrual cycles may be much less frequent than in contemporary Western populations
(Strassmann, 1997).
(iv) There is no clinical diagnostic tool able to discern menopausal status through measuring hormone levels.
While follicle-stimulating hormone (FSH) levels may be diagnostic for cases of early menopause (<45), FSH
levels are unreliable for assessing menopausal status owing to fluctuations in levels throughout
peri-menopause (FSRH, 2017; NCC-WCH, 2015). Additionally, levels of the anti-mullerian hormone (AMH), even
in multiple assessments, are unreliable for measuring ovarian reserve, owing to the wide variation in levels of
AMH within populations, as well as lack of a uniform AMH decline (de Kat et al., 2017).
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age at menopause has been associated with early menarche (G. D. Mishra et al., 2017; Ruth et al.,
2016) and nulliparity (Duarte, de Sousa, Cadarso-Suarez, Rodrigues, & Kneib, 2014; G. D. Mishra
et al., 2017), while increasing parity (number of pregnancies) is associated with later age at menopause
(Duarte et al., 2014; Gold et al., 2001; G. Mishra, Hardy, & Kuh, 2007; G. D. Mishra et al., 2017).
Various markers of lower socioeconomic status or indicators of stress both in early life (household
crowding; father’s social class; parental divorce, poor cognitive ability, maternal smoking; perception
of being thin; R. Hardy & Kuh, 2005; G. Mishra et al., 2007; Ruth et al., 2016) and in later life (edu-
cational status, regional purchasing power; Duarte et al., 2014; Schoenaker, Jackson, Rowlands, &
Mishra, 2014) are associated with an earlier age at menopause. Those relationships are not mediated
by the correlation between age at menarche and poor early life conditions given that most studies con-
trol for age at menarche (Schoenaker et al., 2014). Age at menopause is consistently associated with
lifestyle factors – smoking has a strong association with earlier age at menopause (Gold et al.,
2001, 2013; R. Hardy & Kuh, 2002; Laisk et al., 2018; Ruth et al., 2016; Schoenaker et al., 2014),
while there is a weak association between lower body mass index and earlier age at menopause
(Henderson, Bernstein, Henderson, Kolonel, & Pike, 2008). Whether these different associations are
globally salient is unknown, however, given that most epidemiological data are derived from clinical
studies conducted in high-income countries.
There is currently no overarching framework for explaining why age at menopause correlates with
reproductive, socioeconomic and lifestyle factors. Further, knowledge and theories from physiology,
epidemiology and evolutionary ecology are not usually considered together. However, if one is to
understand both why and how menopause timing varies, it is necessary to account for determinants
at multiple levels. To do this, a human evolutionary ecology approach, drawing on the Mayr–
Tinbergen Framework accounting for both ultimate and proximate causes of diversity together, offers
a promising avenue (Laland, Sterelny, Odling-Smee, Hoppitt, & Uller, 2011). In the next section we
harness this model by considering both current knowledge of the physiology of menopause (proxim-
ate) and current evolutionary theories for the evolution of early reproductive cessation (ultimate) to
propose a new understanding of diversity in menopause timing in humans, i.e. the age at FMP.
2. Integrating ultimate and proximate explanations
In this section, we seek to answer the ultimate question ‘Why does variation in age at natural menopause
exist?’ together with the proximate question ‘How does variation in age at natural menopause occur?’ In
other words, we aim to integrate proximate understandings of ovarian ageing with evolutionary, histor-
ical approaches to menopause timing, which include both adaptationist (i.e. menopause timing has fit-
ness benefits) and by-product (i.e. menopause timing has no fitness benefits) hypotheses (Nesse et al.,
2010; Stearns, 2012). Recent studies on menopause timing view age at menopause as a facultative adap-
tation – i.e. menopausal age varies in response to ecology in a way that maximises fitness (Chan, Gomes,
& Singh, 2020; Galbarczyk & Jasienska, 2013; Skjaervo & Roskaft, 2013; Yang, Arnot, & Mace, 2019).
Those studies are generally silent with regards to physiological understandings of ovarian ageing, how-
ever. In contrast, the hypothesis viewing human menopause as an evolutionary by-product of the selec-
tion for an elongated lifespan is consistent with the finding that ovarian ageing is constrained by somatic
processes rather than triggered (Box 2). In this way, the determinants of age of natural menopause may
be similar to the genetic, developmental and ecological determinants of somatic ageing.
Physiological understanding of menopause timing (proximate approach)
At the physiological level, the transition towards menopause is generally understood in terms of the
processes of ovarian ageing and follicular atresia – the apoptosis (or programmed cell death) of oocytes
(egg cells) (Narkwichean et al., 2017). Ovarian ageing is the process whereby the ovaries decline in their
ability to recruit and develop successful oocytes (Wang, Zhang, Jiang, & Seli, 2017). Ovarian ageing
adversely affects female fertility, reducing the probability of successful pregnancy owing to increasingly
poor quality of follicles. The follicle is the cellular structure containing both the oocyte and surrounding
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granulosa cells and is recruited during the follicular phase of the menstrual cycle. If the follicle is of low
quality, it will undergo atresia – programmed cell death – hypothesised to be under the control of the
supporting granulosa cells (Banerjee, Banerjee, Saraswat, Bandyopadhyay, & Kabir, 2014; Tatone &
Amicarelli, 2013). As the ovary ages, both the quantity and the quality of follicles decreases
(J. J. Zhang et al., 2016), a process referred to as follicular depletion. At menarche the number of fol-
licles is approximately 300,000–400,000 and reduces to below 1000 at menopause (Forman, Mangini,
Thelus-Jean, & Hayward, 2013). The ovary loses follicles in two ways: ovulation and follicular atresia.
As ∼400 follicles are released through ovulation during the reproductive lifespan, the main source of
follicle loss during the lifetime is atresia (Forman et al., 2013), with the rate of follicle loss also
being influenced by multiple factors. Thus, while menopause is co-produced by ovarian ageing and fol-
licular depletion together, ovarian ageing is constrained by somatic ageing of the follicle (Box 2).
Follicular depletion becomes implicated in determining the age at menopause when depletion
causes the number of follicles to be below that required to support menstruation (Leidy, Godfrey, &
Sutherland, 1998). At this point, menstrual cycles become dysregulated and ultimately cease.
Conventional understandings of follicular atresia rates have considered the rate to be biphasic –
with accelerated rates of atresia occurring beyond the age of 35 (Leidy et al., 1998). This, however,
is shown to be the result of misinterpreting plots of follicular atresia rates (Leidy et al., 1998).
Rather, accelerated rates of follicular atresia tend to occur much later, and are more likely within sev-
eral years of the onset of menopause (Leidy et al., 1998). This suggests that processes underpinning the
process of follicular atresia are key to the transition towards menopause.
The rate of follicular atresia is potentially influenced by the inflammatory profile of the menstrual
cycle: ovulation is characterised by inflammation of the ovaries, while menstruation has been deemed a
‘massive inflammatory event’ (Alvergne & Högqvist Tabor, 2018). Inflammation is a major determin-
ant of the ageing process because it releases ROS, which are free radicals implicated in the aetiology of
many non-communicable diseases through the promotion of cell senescence (Franceschi & Campisi,
2014). It remains to be investigated how repeated cycles of ovulation and menstruation influence age-
ing of the granulosa cells and thus follicular atresia. Diversity in cyclical life-history owing to anovula-
tory cycles, pregnancies or hormonal contraceptives is likely to be important for explaining patterns of
reproductive senescence and the onset of menopause.
Box 2: Germ cells are well protected against ageing forces, but the somatic cells of the follicle are not
Perhaps one central issue to integrating ovarian ageing with somatic processes of ageing is that the oocyte itself is a
germ cell. While the oocyte may possess multiple defence mechanisms against ageing, the somatic granulosa cells
which surround the oocyte in the follicle are subject to somatic ageing. As the somatic granulosa cells decrease in
quality, the quality of the overall follicle (including the oocyte itself) decreases and is at risk of undergoing apoptosis.
Ovarian ageing is often centred on the role of mitochondria, exploring the role of dysregulated respiration in the
ageing process. Mitochondria are responsible for the energy production and also producing damaging reactive oxygen
species (ROS) and reactive carbonyl species through respiration. Primordial follicles can be kept in a state of arrested
prophase for upwards of 50 years and so there is potential during this arrest for damage to accumulate in the oocyte
while it is quiescent (Hammond et al., 2016). However, the oocyte itself is well protected against oxidative damage, and
it has been suggested that localised antioxidant production around the oocyte offers adaptive protection against DNA
damage caused by ROS and during its suspended lifespan (Hammond et al., 2016; D. D. Zhang et al., 2015). Localised
production of melatonin in the ovary, which has antioxidant properties, also supports the presence of protective
measures in the ovary against the impact of long-term exposure to ROS (Tamura et al., 2017). As such, mitochondrial
DNA in the oocyte is not shown to accumulate mutations during ovarian ageing in the way predicted if there were no
methods of oxidative shielding (Boucret et al., 2017).
The granulosa cell therefore becomes the locus for attention on processes leading to follicular atresia, as well as
the site of increasing genomic instability of ageing oocytes (Banerjee et al., 2014; Boucret et al., 2017; May-Panloup
et al., 2016; D. D. Zhang et al., 2015). Follicular atresia is initiated through the granulosa cells, which accompany the
oocyte from oogenesis to the creation of the antral follicle. Thus, the process of follicular atresia depends on the
quality of the granulosa cells – not the oocytes. The senescence of the somatic cells in the ovarian microenvironment
becomes the locus for studying determinants of ovarian ageing (Banerjee et al., 2014; Tatone & Amicarelli, 2013).
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Evolutionary understanding of menopause timing (ultimate approach)
Why menopause timing varies has attracted little research to date (but see (Laisk et al., 2018) for a
review), most research focusing on the question of why menopause – defined as the permanent cessa-
tion of fertility – exists at all in humans and in some other species. Adaptationist perspectives consider
the paradoxical occurrence of fertility cessation to hold an adaptive benefit given females do not directly
increase their fitness consistently throughout their adult life. In this framework, menopause – by enab-
ling women to avoid later-life reproduction – reached fixation in humans because it conferred fitness
benefits through increased alloparental care and decreased reproductive conflict and mortality risk
(Cant & Johnstone, 2008; Cant, Johnstone, & Russell, 2009; Croft et al., 2017; Ellison, 2001; Hawkes
& Coxworth, 2013; Hawkes, O’Connell, Jones, Alvarez, & Charnov, 1998; Kirkwood & Shanley,
2010; Packer, 2001; Peccei, 2001; Williams, 1957). In contrast, by-product theories view the emergence
of menopause as an epiphenomenon – a spandrel (Gould & Lewontin, 1979) – co-produced by the
finite nature of a female’s oocyte supply and extended lifespan longevity, which allow females to outlive
this supply (Cohen, 2004; Ellison, 2001; Peccei, 2001). In this view, menopause emerged in human
females because somatic longevity increased, while reproductive longevity did not. Our purpose here
is not to dispute which framework is more salient for understanding the emergence of menopause,
as indeed processes underpinning the emergence and the maintenance of traits might differ. Rather,
we use those hypotheses as a guiding framework for explaining why age at menopause varies.
Recent research into the timing of menopause has taken an adaptive stance. In this view, meno-
pause is a facultative trait where menopause timing responds to ecological factors such as daughter’s
reproductive success, dispersal patterns and living in the matrilineal/patrilineal household (Cant &
Johnstone, 2008; Skjaervo & Roskaft, 2013; Yang et al., 2019). Studies have found little support for
modification of menopausal age based on either mediating factor, nor have they given suggestions
for physiological mechanisms to explain how age at menopause could be affected by factors such as
dispersal and daughter’s reproductive success. Additional adaptationist theories, such as the ‘shifting
mate choice/shifting menopause’ hypothesis, posit that variation in age at natural menopause occurs
in response to later age of reproduction, through the removal of deleterious alleles selecting for meno-
pause, which have accumulated owing to male preference for younger mates (Chan et al., 2020).
Fundamentally, adaptationist perspectives have not proposed or found a genetic or physiological path-
way producing a cascade which triggers reproductive senescence during midlife and would allow
menopause timing to be facultative.
Comparatively, menopause timing has seldom been explored from the premise that menopause is a
by-product of selection on longevity, following the decoupling of somatic and reproductive lifespan in
human females. This may be due to the unclear directionality of mechanisms considered to be
involved in the decoupling of reproductive and somatic lifespan – a prerequisite for this hypothesis.
Female reproductive skew, and the front loading of reproductive events, is invoked as a mechanism
that could be the cause of the evolution of menopause as it would decrease selection on extended
reproductive lifespan (Peccei, 2001). However, given that the preference for younger females is
found in humans (Chan et al., 2020; Takahashi, Singh, & Stone, 2017), but not particularly in chim-
panzees (Takahashi et al., 2017), the human male mate preference is likely a derived trait and may be
the outcome, rather than the cause, of early reproductive cessation in women. Nevertheless, the length
of the female reproductive lifespan in humans is comparable with that of other species of similar body
sizes (Peccei, 2001), while the length of somatic lifespan is not, suggesting that extended longevity is a
derived trait in humans, while the length of the reproductive lifespan is not. This raises the possibility
that age at menopause (rather than age at last birth) is at least partly determined by processes under-
pinning somatic ageing. In this line, ageing of the human female reproductive capacity is constrained
by somatic ageing of the follicles (Box 2), as measured by the rate of follicular atresia. The somatic cells
supporting reproduction age faster than the oocyte and the ovary are because they are less well pro-
tected from oxidative damage. Thus, exposure to factors implicated in increasing longevity could
increase reproductive lifespan.
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Towards a multilevel framework
Patterns of diversity in age at menopause are poorly understood. To address this, we propose a multi-
level, interdisciplinary framework, combining proximate, physiological understandings of ovarian age-
ing with ultimate, evolutionary ecological perspectives on ageing. We hypothesise that evolutionary
ecological factors known to influence somatic ageing variation (the genetics of longevity, early life
environments, infections) can also explain rates of ovarian ageing, follicular depletion and diversity
in the onset of menopause.
Overall patterns of ageing and senescence are understood evolutionarily through the Disposable Soma
hypothesis (Kirkwood, 1977, 1999), where the body’s capacity to accumulate deleterious senescent cells is
attributed to declining selection pressure of maintenance mechanisms as age increases, owing to increas-
ing extrinsic mortality risk (Kirkwood, 1999). Through the evolutionary lens, age-related health decline
results from accumulated damage and suboptimal functioning of bodily systems on the molecular, cel-
lular and organ levels (Kirkwood, 1999). When menopause becomes conceptualised as the by-product
of ageing of the reproductive system, by-product hypotheses of menopause are compatible with current
physiological understandings of ageing and cellular senescence. Exploration into variation therefore
allows overarching theories of ageing rate variation to be applied to the female reproductive system.
Rates of cellular senescence can vary depending on the interaction between an organism and
ecological factors (e.g. food availability, stress, pathogen load), producing patterns of ageing rates
which vary within and between populations. Ecological factors might also influence women’s cyclical life-
history, producing diversity in anovulatory cycles, pregnancies or hormonal contraceptives, which are
likely to be important for explaining patterns of reproductive senescence and the onset of menopause.
These ecological factors will be explored in the next section in relation to current epidemiological under-
standings of variation in age of natural menopause, and with suggestions for further research.
3. Understanding patterns of menopause timing
In this section, we review the role of genetic, environmental and reproductive factors in explaining
diversity in somatic senescence rates – ecological interactions which influence somatic ageing. This
follows from the previous section where we suggest how these might be applied to understanding
diversity in ovarian ageing. We show that there are common genetic factors between extreme longevity
and age at menopause with regards to genes mediating metabolic profiles, metabolism and oxidative
shielding. Following research showing that the early life environment influences the pace of reproduct-
ive development and life-history ‘strategy’, we hypothesise that poor early life environment may result
in lower embodied capital, and thus earlier age at menopause. Finally, we propose that women who
experience a higher number of cumulative ovulatory menstrual cycles may experience earlier age at
menopause through the cumulative exposure of localised inflammation in the female reproductive
organs during ovulation. We show that the phenotype of age at menopause may be the result of an
interaction between genetic, ecological factors and the cycling life-history.
Genetic factors
Genetic factors between ovarian ageing and overall somatic ageing show similarities in the biochemical
pathways in which they are implicated. Human longevity is a complex biosocial trait, with genetics
being highly context-dependent and rates of senescence resulting from a dynamic process (Giuliani,
Garagnani, & Franceschi, 2018). There are no genes which ‘code for’ longevity in humans (Giuliani
et al., 2018), and associations between alleles and longevity occur where such alleles produce a pheno-
type conducive for long life, especially amongst centenarians (individuals who have lived to age 100).
Such phenotypes include metabolic profiles characterised by preserved glucose tolerance and insulin
sensitivity; compressed morbidity and disability in later life, and general avoidance or postponement
of age-related diseases; and decreased DNA methylation compared with others of the same chrono-
logical age (Giuliani et al., 2018). Such phenotypes are conducive of reduced levels of accumulated
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damage contributing to the functioning of bodily systems on the molecular, cellular and organ levels.
These phenotypes may therefore promote both somatic longevity and reproductive longevity, thus
postponing age at menopause.
Genetic factors which have been identified as contributing to the phenotype of somatic longevity,
reproductive longevity or both include the following:
• APOE: the APOE gene codes for apolipoprotein E, which helps maintain structural integrity and
function of cholesterol rich lipoproteins. The protein structure of APOE varies and is found to exist
in three different isoforms which alter its function. Isoforms APOEe2, APOEe3 and APOEe4 are
positively associated, not associated or negatively associated with longevity, respectively (Abondio
et al., 2019). Regarding menopause, association between isoforms and reproductive longevity has
been inconclusive. Heterozygous APOEe3/4 carriers show a delayed age at menopause compared
with APOEe3/3 carriers in a Chinese population (Meng et al., 2012). Both APOEe4 and APOEe2
isoforms have been associated with predicted earlier age at menopause amongst Iranian females
and women of European descent, respectively (Koochmeshgi, Hosseini-Mazinani, Morteza
Seifati, Hosein-Pur-Nobari, & Teimoori-Toolabi, 2004; Tempfer et al., 2005).
• Sirtuins: Sirtuins are proteins which modulate metabolism, cell proliferation and genome stabil-
ity. Regulation of several sirtuin genes – SIRT5 and SIRT7 – has been found to have a positive
association with longevity, while a minor SIRT6 homologous allele, affecting its function, has
been associated with decreased lifespan (Giuliani et al., 2018). Variation in sirtuin regulation
has been linked to reproductive longevity, with downregulation of SIRT1, SIRT3 and SIRT6
being linked to an increased rate of ovarian ageing (J. J. Zhang et al., 2016).
• Mitochondrial Haplotype J: Mitochondrial DNA Haplotype J is hypothesised to reduce the out-
put of both ATP (the product of respiration) and ROS. The mtDNA J haplotype has been posi-
tively associated with somatic longevity in European populations (Giuliani et al., 2018), and was
underrepresented amongst French women with depleted ovarian reserves undergoing fertility
treatment (May-Panloup et al., 2014), suggesting it plays a role in reproductive longevity.
• FOXO3: FOXO3 is a gene which downregulates activity on the IGF1 pathway, helping to main-
tain a metabolomic profile conducive to longevity (Giuliani et al., 2018). Associations between
expression of FOXO3 and reproductive longevity are unknown.
• IL6: Modulation of interleukin 6, a multifunctional cytokine associated with inflammatory
responses by a minor allele has also been associated with longevity and the aetiology of
age-related disease (Giuliani et al., 2018). Associations between IL6 modulation and reproductive
longevity are unknown.
Additional single nucleotide polymorphisms associated with age at menopause have been linked to
genes involved in hormonal regulation, immune function and DNA repair pathways (Stolk et al.,
2012). A candidate gene located on the Human Leukocyte Antigen transcript has been associated
with age at menopause as well as Type-1 diabetes and rheumatoid arthritis (Stolk et al., 2012).
Such a gene implicates a pro-inflammatory component to physiological pathways mediating rates of
ovarian ageing (Stolk et al., 2012). BRCA1 mutations also confer an increased rate of ovarian ageing,
hypothesised to be due to increased rates of double-strand DNA breaks in follicles, causing subsequent
increase in the rate of follicular atresia (Box 2, Figure 3; Lin, Titus, Moy, Ginsburg, & Oktay, 2017).
Determinants of longevity and somatic senescence are hugely complex, with genetic factors only
explaining a small proportion of variation in longevity (Giuliani et al., 2018). GWAS-identified loci
and their related function only explain 2.5–4.1% of population variation in the age at menopause
(Stolk et al., 2012). The genetic contribution to age at menopause, and overall senescence rates may
be overpowered by ecological and environmental factors and so must be considered in relation to
other exogenous factors. Despite the low contribution genetic variation makes, these studies indicate
that processes of non-communicable diseases and ovarian ageing are underpinned by similar meta-
bolic and inflammatory processes.
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Ecological factors
Rates of age-related health decline are in part mediated by an individual’s ability to accrue somatic
capital – a factor dependent on environmental constraints on energy available for their growth and
development. Somatic capital can be understood as the energetic investments made by the body in
growth and maintenance of tissue beds and organs (Kaplan, Lancaster, & Robson, 2003), which
will depreciate over time through wear and tear. As the body’s ability to maintain cellular and tissue
function decreases over time, mechanisms in the ageing body must rely on their existing somatic cap-
ital to ensure optimal function is maintained. Somatic capital accrual can be influenced by the life his-
tory strategy of the individual. Life history theory (Ellison, 2003; Gluckman, Beedle, & Hanson, 2009)
broadly describes patterns of growth, reproduction and mortality in an individual’s life and in a given
environment. One particularly influential concept in life-history evolution is that of the ‘fast–slow con-
tinuum’, which accounts for the fact that many life-history traits co-vary across and within species
(Stearns, 1992). Age at menopause may therefore be understood as an outcome of a life-history
strategy, itself contingent on the somatic capital of the female reproductive system, determined by eco-
logical factors (e.g. food availability, stress, pathogen load). Using a life history theory approach allows
investigating whether variation in age at menopause reflects overall rates of ageing in the body or is
specific to reproductive senescence.
Extrinsic mortality
Life history theory posits that, in environments with high extrinsic mortality (i.e. mortality independ-
ent of an individual’s phenotype), metabolic investment in reproduction is prioritised at the expense of
other fitness components (somatic maintenance, growth; Stearns, 1992). This leads to the acceleration
of an organism’s life-history (hence a ‘fast life-history’ strategy; Hidaka & Boddy, 2016; Nettle, 2010;
Stearns, Ackermann, Doebeli, & Kaiser, 2000) and is hypothesised to affect rates of ageing and the
development of age-related diseases. In humans, age at first birth in England is younger in deprived
Figure 3. Agents which influence ovarian ageing. Agents with their respective effect on rates of ovarian ageing. ROS (reactive
2oxidative species) produce oxidative stress, which contributes to cellular senescence and cell apoptosis. Conversely, agents
which contain antioxidants improve overall mitochondrial function, slowing down the rate of cellular senescence. However,
while some physiological processes are known, there has been no ecological study accounting for fast or slow ovarian ageing.
Lists of references are provided in the Supporting Information.
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areas compared with more affluent areas, which is interpreted as a response to the ecological context of
poverty (Nettle, 2010), with girls from moderately stressful environments of nutritional inadequacy
experiencing accelerated pubertal timing (Ellis, 2004). In turn, low embodied capital of the reproduct-
ive system may cause suboptimal tissue defence (Noguera, 2017) against the oxidative stress of men-
struation and reproduction, increasing rates of follicular atresia. This may ultimately accelerate
reproductive ageing towards menopause. In comparison, those living in energy-rich, low-mortality
environments may accrue higher somatic capital owing to a slower life history strategy (Ellis, 2004).
Higher socioeconomic living conditions may therefore be associated with later age at menopause
given the prolonged ability for tissue maintenance in those with higher somatic capital.
It is important to clarify at this point that life history strategies are often used in a behavioural con-
text, to explain patterns of behaviour – often related to reproduction (Nettle, 2010). Here, we use life
history strategies to refer to the allocation of physiological resources, contributing to the embodied
capital of the individual rather than in a more behavioural context.
Fast/slow life history theories as a predictive framework are in line with trends in epidemiological
studies where earlier age at menopause is found amongst low/middle-income populations, as well as
amongst those who were exposed to poor environmental conditions earlier in life (Duarte et al., 2014;
R. Hardy & Kuh, 2005; G. Mishra et al., 2007; Ruth et al., 2016; Schoenaker et al., 2014). Furthermore,
in Western populations, earlier age at menopause has been associated with an increased risk of
cardiovascular diseases (CVD), atherosclerosis, stroke and osteoporosis (Forman et al., 2013;
Schoenaker et al., 2014) while later menopause has been associated with both a reduced risk of
CVD and all-cause mortality and an increased risk of breast and ovarian cancer and osteoporosis
(Forman et al., 2013; Henderson et al., 2008; Ossewaarde et al., 2005; Schoenaker et al., 2014).
Finally, studies into oestrogen-receptor negative breast cancer rates suggest that a fast life history strat-
egy may result in a higher incidence of breast cancer amongst women of lower socioeconomic status
(Hidaka & Boddy, 2016).
Infectious diseases
Additional metabolic trade-offs between growth, maintenance and reproduction can occur in the
presence of infectious disease where energy is allocated to the immune system at the expense of
other bodily functions (Ellison, 2003). Sievert has previously explored the relationship between age
at menopause and exposure to infectious diseases over the life course amongst Bangladeshi women liv-
ing in London. They were found to have a significantly earlier age at menopause than other women liv-
ing in London, with earlier age being strongly associated with a history of infectious disease exposure on
multiple occasions (Sievert, 2014). As immune defences against pathogens are energetically costly,
pathogen load may also contribute towards reducing bodily investment in the growth and maintenance
of the body. Studies researching the effect of prolonged infection on age at menopause show a younger
age at menopause amongst women with HIV compared with women without HIV in the Bronx
(Schoenbaum et al., 2005), although this result is not entirely consistent (Conde, Pinto-Neto, &
Costa-Paiva, 2008). There is potential for expanding research into the influence of infectious diseases
on age at menopause by studying (a) the impact of infections earlier versus later in life, (b) population-
level patterns where malaria is endemic and (c) and immunocompromised populations.
Cyclical reproductive life history
Variation in rates of ovarian ageing may result from the cumulative exposure of the female reproduct-
ive system to cyclical inflammation, which may vary across ecologies. Reproduction in human females
is characterised by cyclical fertility, with menstrual cycles completed between approximately 24 and 38
days (Alvergne & Högqvist Tabor, 2018), with the end of non-conceptive cycles characterised by men-
struation, a massive inflammatory event. Localised inflammation also occurs in the ovaries during the
inflammation-mediated repair of the corpus luteum immediately after ovulation (Alvergne & Högqvist
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Tabor, 2018). Furthermore, the ovaries are the site of oestrogen production – hormones which can act as
pro-inflammatory, depending on dose. Through menstrual cycling, cyclical, systematic inflammation
may contribute to damage of the granulosa cells and ovarian microenvironment, resulting primarily
in the accelerated senescence of the female reproductive function relative to other organs of the body.
There is some evidence that ovarian ageing rates may vary according to the total number of men-
strual cycles experienced in a female’s reproductive lifespan. First, high cumulative levels of oestrogen
exposure are known to be a risk factor for the development of oestrogen receptor-positive breast, ovar-
ian and endometrial cancers (Aktipis, Ellis, Nishimura, & Hiatt, 2014; Jasienska, Bribiescas, et al.,
2017; Jasienska, Sherry, Holmes, & SpringerLink, 2017; Strassmann, 1999). Given tumorigenesis
also operates through cellular damage and mutations, it is not implausible to consider the effect of
concentrated cumulative oestrogen exposure on cellular senescence of the reproductive organs.
Second, preliminary epidemiological data show that nulliparity (as a discrete entity) is significantly
associated with earlier ages of menopause (Duarte et al., 2014; G. D. Mishra et al., 2017). Normally
cycling nulliparous women who are not taking any form of hormonal contraception do not experience
the gaps in ovulation that occur during the gestation period and breastfeeding. This suggests that the
female reproductive life history should be considered in its entirety – e.g. as total number of menstrual
cycles experienced – rather than as a composite of discrete entities (e.g. age at menarche, parity, breast-
feeding and use of hormonal contraception) as it is often approached within epidemiological studies.
This approach has already been used in several epidemiological studies of breast cancer, where higher
numbers of cumulative menstrual cycles have been associated with an increased risk of breast cancer
(Chavez-MacGregor et al., 2005; Clavel-Chapelon & Grp, 2002; Rautalahti et al., 1993).
How ecology influences a woman’s cumulative exposure to cyclical inflammation is poorly under-
stood. A 1994 study estimate that women in contemporary Western populations experience up to 400
cycles during the lifetime, compared with a median of 94 within a contemporary natural fertility popu-
lation (Strassmann, 1997). In the absence of data on the cycling life-history, reproductive traits across
the lifespan could be used as a proxy to estimate a woman’s cumulative exposure to inflammatory
menstrual cycles. Note that ideally, it is the number of ovulatory, as opposed to anovulatory, cycles
that is the most relevant measure. Proximate determinants of the number of menstrual cycles
might themselves be the outcome of life history strategies explored earlier (see Ellis, 2004), but similar
life-history ‘strategies’ may have different impacts on the number of menstrual cycles depending
on sociocultural contexts (i.e. availability of contraception, norms around breastfeeding etc.; Ellis,
2004), although these life-history strategies are not necessarily prescriptive (Nepomnaschy,
Rowlands, Costa, & Salvante, 2020; Sheppard & Van Winkle, 2020). Nevertheless, life-history and
reproductive cyclicity approaches are not mutually exclusive.
Accounting for the cost of cumulative menstrual cycles may have implications for evolutionary models.
First, it adds nuance to what may count as a ‘cost of reproduction’ – this is often referred to as the impact
of reproduction and pregnancy on the female body, at the expense of physiological functioning (Ryan
et al., 2018). While pregnancy may incur a physiological cost to somatic functioning (Ryan et al.,
2018), it may also be protective over ovarian function with regards to the onset of menopause (Duarte
et al., 2014; G. D. Mishra et al., 2017). Thus, cyclical menstruation and pregnancy may be better consid-
ered as separate entities rather than falling under the all-encompassing ‘cost of reproduction’. Second,
given the physiological processes of reproductive and somatic ageing are physiologically similar, reproduc-
tion might entail costs not only for somatic senescence, a trade-off often studied by evolutionary biologists
(see T. B. L. Kirkwood & Westendorp, 2001), but also for reproductive senescence. While cyclical inflam-
mation confers fitness benefits early in life, more frequent cyclical ovulation in humans might directly
influence the onset of menopause through the antagonistic pleiotropic effects of cyclical inflammation.
In this section, we have explored possible evolutionary ecological determinants of diversity in meno-
pause timing. While much of the literature in this review comes from studies in high-income countries,
the framework we have developed here may help formulate hypotheses for studies of populations in
lower-income countries. Future research investigating how factors such as socioeconomic status, poverty,
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food insecurity and infectious diseases interact with life history and cyclical reproductive life histories
may help expand understandings of variation in age of natural menopause within different populations.
4. Implications for public health
As ageing populations are perceived to present challenges to the maintenance of population health,
healthcare provision, demographic structure and society, there is increasing importance placed on
research aiming to understand and predict patterns of ageing (USC Programme on Global Ageing
& Policy, 2018). However, current public health approaches towards understanding diversity in the
experience of menopause (age and symptoms) and its impact on health and overall wellbeing are
scarce. Here we show that an ecological approach to variation in menopause might help with (a) nuan-
cing assumptions about the ‘normal’ menopause, (b) understanding the relationship between meno-
pause and health decline, (c) interrogating whether earlier menopause and diseases of old age originate
from the same ecological determinants of health and (d) how understanding variation in menopause
experience can benefit wider studies into successful ageing.
Stimulating public health research into the diversity of menopausal experience
Despite a substantial focus within public health on ageing (Beard & Bloom, 2015), menopause as a facet
of the female ageing experience is often excluded from research questions into ageing and subsequent
public health interventions (e.g. breast cancer screening). For instance, out of the 15 ageing cohort studies
found on the Gateway to Global Ageing Data (USC Programme on Global Ageing & Policy, 2018), a
harmonised dataset aiming at providing resources to support cross-national research on ageing, only
five studies collected any form of data on menopause from their female participants. The questions
and cohort studies which did include menopause-related variables are found in Table 1. The observation
that menopause is excluded from ageing cohort studies, which premise themselves on collecting data on
the multifactorial nature of the ageing experience, reveals the absence of menopause from public health
discourses of ageing, which suggests that its impact on the ageing experience is neglected. Any relation-
ships existing between menopause and health are unable to be identified, allowing prevalent biomedical
assumptions to prevail. Ignorance of menopause as a facet of female ageing creates a measurement trap,
in which lack of information is both the cause and the effect of continuing exclusion (Graham, 1998).
Since the 1990s, several longitudinal studies have been started, many with the specific aim of under-
standing the impact of HRT usage on later life health among post-menopausal women such as the
Women’s Health Initiative (Nabel, 2013; Rossouw, Anderson, & Oberman, 2003) and Million
Women Study (The Million Women Study Collaborative, 1999). Study of Women’s Health Across
the Nation and the International Collaboration for a Life Course Approach to Reproductive Health
and Chronic Disease Events are currently collecting and synthetising health data on peri- and post-
menopausal women. Inclusion of questions around the menopausal experience in ageing cohort stud-
ies, and expansion of menopause-related research questions beyond HRT and later-life health out-
comes, will help to corroborate the data collected by the Study of Women’s Health Across the
Nation and International Collaboration for a Life Course Approach to Reproductive Health and
Chronic Disease Events and improve the robustness of research into menopause.
Reframing the menopausal transition as normal
Understanding menopausal variation can help alleviate the assumptions still present within the biomed-
ical approaches of menopause. Biomedical perspectives of menopause were for most of the twentieth
century predicated on the assumption that menopause and the oestrogen-deficient body were inherently
‘risky’ (Harding, 1997; Lock, 1993), with this risk to be countered through the prescription of HRT dur-
ing the post-menopausal life stage. While the Women’s Health Initiative and Million Women Study
revealed the health risks associated with indiscriminate long-term prescription of HRT (to the extent
that the experimental studies had to be prematurely ended; Nabel, 2013), assumptions surrounding
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the causality of post-menopausal health issues as well as a lack of recognition of menopause experience
variation may arguably still persist within Western biomedicine and public health.
Further, public health research into menopause variation can primarily help nuance the designation
of the menopausal transition as ‘normal’ or ‘pathological’. Current UK guidelines state that any woman
entering menopause at age <40 is experiencing premature ovarian insufficiency while those entering
menopause at age <45 are experiencing early menopause (NCC-WCH, 2015). As there is little consensus
on hormonal diagnosis of ovarian ageing (Box 1) and given that variation in age at menopause exists
within and between populations, normal ‘earlier’menopause in some women may be accidentally patho-
logised, while abnormal but ‘later’ menopause may remain undiagnosed in others. Current biomedical
understandings of ‘normal’ menopause are predicated on normative views of how a ‘normal’ body
should behave (Wiley & Cullin, 2020). Gathering data to explore the true variation of menopausal
age within and between populations will allow this assumption to be challenged.
Rethinking menopause as the by-product rather than the catalyst of biological ageing
Age at menopause is associated with varying health outcomes, with earlier age at menopause being gen-
erally associated with increasing risk of all-cause mortality (Forman et al., 2013; Schoenaker et al., 2014).
Table 1. Menopause-related variables in the Gateway to Global Aging Data, produced by the USC Program on Global
Aging, Health & Policy, with funding from the National Institute on Aging
Cohort Region Years Variables
TILDA Ireland Pilot Gone through menopause;
age menopause started;
taken prescription hormones;
Number of years taking hormones;




NICOLA Northern Ireland 2015 Gone through menopause;
age menopause started;
used prescription hormones;
number of years taking hormones;
number of years took hormones
2017 Used hormones since menopause;
still using/stopped using hormones;
number of years taking hormones;
number of years took hormones
HRS USA 2008 Current stage of menopause;




2016 Current stage of menopause;
how oldwhenfinished menopause;
year finished menopause
CHARLS China 2011 Age at menarche;
has menopause started?
2013
2015 age at menarche;
has menopause started?;
age at menopause
CRELES Costa Rica 2005 age at menarche;
age at last menstruation;
ever used HRT to treat menopause for 3+ years2010
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Thus, age at menopause can be used to identify at-risk groups of older women, who could then be tar-
geted with preventative screening programmes and treatment against associated diseases such as cancers,
CVD and osteoporosis prior to any manifestation of disease. However, risk factors for health and disease
that accelerate biological ageing may also contribute to earlier age at menopause rather than menopause
itself being the catalyst for biological ageing (Levine et al., 2016). For instance, menopause has been asso-
ciated with epigenetic processes linked to cellular senescence and ageing when epigenetic biomarkers
of methylation are compared with chronological age (Levine et al., 2016; USA & European populations,
n = 3110). The epigenetic age at blood was found to have a negative correlation with age at menopause,
which supports observational studies that found that for every one-year increase in age at menopause,
the age-adjusted mortality rate decreases by 2% (Levine et al., 2016). In this study, there is a suggestion
of directionality, with post-menopausal women who had late onset of menopause found to be epigen-
etically younger than women with early onset menopause. However, risk factors for health and disease
that accelerate biological ageing may also contribute to earlier age at menopause rather than menopause
itself being the catalyst for biological ageing (Levine et al., 2016). Such research nuances prevailing
assumptions around menopause being the cause or catalyst of poor health and disease in later life.
Contrasting with contemporary biomedical perspectives, an ecological approach to understanding
diversity in the onset of menopause may show that correlations between earlier menopause and dis-
eases of old age originate from the same life history determinants of health, encompassing somatic
capital and life history strategies and the wider sociocultural determinants of health. Such life course
studies would fall into the emergent discipline of evolutionary public health (Wells, Nesse, Sear,
Johnstone, & Stearns, 2017), where both proximate and ultimate explanations into patterns of popu-
lation health and disease are considered within the theoretical framework (Wells et al., 2017). An
understanding of how ecological and evolutionary contexts throughout life can help explain patterns
of health in older age within and between socioeconomic strata, owing to developmentally and envir-
onmentally determined patterns of energy allocation (Wells et al., 2017). Evolutionary public health
allows the integration of menopause timing within overarching understandings of ageing and senes-
cence in life history as well as its inclusion in public health data collection and approaches to ageing.
This is not to say that menopause has no adverse impact on the health of ageing females, but its inser-
tion into large-scale health data collection would allow any risk factors emerging from menopause to
be identified and nuanced, combating the pathologisation of menopause as a whole.
Aside from evolutionary ecological approaches to menopause, there is also scope for integrating
menopause into the wider evolutionary medicine paradigm. Reconceptualising health, from an evolu-
tionary perspective, as a means to an end of reproductive success (Wells et al., 2017) requires the rec-
ognition that reproductive function is intrinsically intertwined with ‘non-reproductive’ health. The
peri- and post-menopausal body can be reconceptualised as the female body with minimal interaction
between the reproductive system and other bodily systems. In doing so, there is incentive to study how
the dysregulation and cessation of the menstrual cycle may impact the immune system (for review see
Alvergne & Högqvist Tabor, 2018), or the aetiologies of non-communicable diseases.
Diversity in menopausal experience and the capacity for successful ageing
While the study of variation may be useful in understanding disease risk, it may be equally important
to consider how and why variation in age and experience affects an individual’s capacity for ‘success-
ful’ ageing (Rowe & Kahn, 2015). There is an increasing awareness of ‘successful ageing’ in Public
Health and Gerontology, which encompasses the social, cultural and psychological impact of growing
older beyond the increasing health risks. In this view, the ageing experience is expanded beyond the
disease risk and frailty to include facets of the ageing experience that are more important to the indi-
vidual (Rowe & Kahn, 2015). Therefore, approaches to menopause as a component of female ageing
should also be expanded beyond focusing on health risks.
Facets of the menopausal experience and wider female ageing are already being studied and could
benefit from taking the existence of variation into account. This includes areas such as: menopause in
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the workplace (C. Hardy, 2019); grandmothering, its impact on familial health and how menopause
may affect the ability to alloparent (Sear, 2016); female personhood during the life course (Pickard,
2019); menopause and sexuality; and more critical medical anthropological perspectives on meno-
pause, biopower and pharmaceutical intervention (Harding, 1997; Padamsee, 2011). Expanding
focus onto how diversity in the experience of menopause impacts the wider social and cultural experi-
ence of growing older will improve the robustness of public health perspectives on women’s ageing,
closer to actual lived experience.
5. Conclusion
The goal of this paper is to stimulate an interdisciplinary, multilevel framework for understanding the
role of evolutionary and ecological factors in shaping diversity in age at natural menopause. By engaging
with the definitions of menopause across disciplines, we can ensure that proximate and ultimate
approaches to menopause are addressing the same phenomenon, i.e. the cessation of menstrual cycles,
rather than broader features of the post-fertile lifespan. We have shown the compatibility of biomedical,
physiological understandings of ovarian ageing with evolutionary theories viewing the emergence of
menopause as a by-product of recent increases in longevity (e.g. the reproductive-somatic mismatch
hypothesis; Cohen, 2004). This suggests that evolutionary hypotheses usually applied to somatic senes-
cence (e.g. the Disposable Soma hypothesis, the antagonistic pleiotropy hypothesis, the embodied-capital
theory) may also become fruitful for understanding patterns of diversity in menopausal traits.
A consistent theme throughout this paper has been to highlight potential areas where menopause
research is lacking, and which can be expanded both in the medical sciences and in human ecological
studies. We also suggest potential implications for approaches towards ageing women’s health in pub-
lic health and the wider medical sciences. We suggest that menopause is currently excluded from pub-
lic health approaches to ageing and that its continued exclusion cannot be justified. Not only should
menopause be measured in ageing cohort studies, but its measurement should be done with the meth-
odological considerations outlined earlier in mind. We also posit that recognition of variation in
menopause may help nuance assumptions surrounding normalcy and the menopause, and the clinical
cut-offs made between ‘normal’ and ‘abnormal’ menopause. We further recognise that through the
application of evolutionary theories of ageing towards menopause variation there is an opportunity
to reconceptualise menopause as a process of ageing, rather than its cause. This might stimulate
novel research questions into which processes underlay both reproductive and overall senescence.
This also stands in contrast to the social construction of menopause as a pathology within Western
biomedicine, and reaffirms the menopausal transition as normal, rather than inherently pathological.
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